KYPROLIS® (carfilzomib) is a prescription medication used to treat adult patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma. KYPROLIS is approved for use in combination with daratumumab plus dexamethasone, dexamethasone or with lenalidomide plus dexamethasone, which are other medicines used to treat multiple myeloma.
The information provided in this section is intended expressly for healthcare professionals in the United States. Click “Yes, I am” to enter if you are a U.S. healthcare professional.
* Achieving [re]remission happens when you get back to remission, when your disease doesn't get worse and you have a complete or partial disappearance of signs or symptoms, after relapse.
What to expect before starting KYPROLIS®
Support for staying on KYPROLIS®
How KYPROLIS® has helped others get back to remission
In clinical studies of patients with relapsed or refractory multiple myeloma, four KYPROLIS® combinations kept the disease from getting worse and helped patients reach at least a complete response better than comparators:
KYPROLIS® given twice a week with DARZALEX® (daratumumab) and dexamethasone kept the disease from getting worse longer than KYPROLIS® and dexamethasone alone. With a median follow-up of nearly 28 months, the median progression-free survival (the length of time from the start of treatment until half of the patients have experienced worsening disease or death) for patients who received KYPROLIS®, DARZALEX®, and dexamethasone was 28.6 months vs 15.2 months for KYPROLIS® and dexamethasone alone. In an earlier analysis with a median follow-up of ~17 months, more patients reached a complete response when they received KYPROLIS® given with DARZALEX® and dexamethasone vs KYPROLIS® and dexamethasone alone (28% vs 10%).
KYPROLIS® given twice a week with dexamethasone kept the disease from getting worse longer than Velcade® (bortezomib) and dexamethasone (median of 18.7 months compared with 9.4 months). More patients reached a complete response or better when they received KYPROLIS® and dexamethasone vs Velcade® and dexamethasone (13% vs 6%).
KYPROLIS® given once a week with dexamethasone kept the disease from getting worse longer than KYPROLIS® given twice a week with dexamethasone (median of 11.2 months compared with 7.6 months). More patients reached a complete response or better when they received KYPROLIS® once a week at a higher dose and dexamethasone vs KYPROLIS® twice a week at a lower dose and dexamethasone (7.1% vs 1.7%).
KYPROLIS® given with Revlimid® (lenalidomide) and dexamethasone kept the disease from getting worse longer than Revlimid® and dexamethasone (median of 26.3 months compared with 17.6 months). More patients reached a complete response or better when they received KYPROLIS® given with Revlimid® and dexamethasone vs Revlimid® and dexamethasone (32% vs 9%).
KYPROLIS® (carfilzomib) can cause serious side effects:
These are not all the possible side effects of KYPROLIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088. 1‑800‑FDA‑1088.
Please see full Product Information.